These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9085405)

  • 41. Impact of state and trait anxiety on the panic response to CCK-4.
    Eser D; Wenninger S; Baghai T; Schüle C; Rupprecht R
    J Neural Transm (Vienna); 2008 Jun; 115(6):917-20. PubMed ID: 18414777
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Megestrol attenuates the hormonal response to CCK-4-induced panic attacks.
    Raedler TJ; Jahn H; Goedeken B; Gescher DM; Kellner M; Wiedemann K
    Depress Anxiety; 2006; 23(3):139-44. PubMed ID: 16470820
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fluvoxamine attenuates panic induced by 35% CO2 challenge.
    Pols HJ; Hauzer RC; Meijer JA; Verburg K; Griez EJ
    J Clin Psychiatry; 1996 Nov; 57(11):539-42. PubMed ID: 8968304
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Functional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety.
    Schunck T; Erb G; Mathis A; Gilles C; Namer IJ; Hode Y; Demaziere A; Luthringer R; Macher JP
    Neuroimage; 2006 Jul; 31(3):1197-208. PubMed ID: 16600640
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder.
    Shlik J; Aluoja A; Vasar V; Vasar E; Podar T; Bradwejn J
    J Psychiatry Neurosci; 1997 Nov; 22(5):332-40. PubMed ID: 9401314
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia.
    Bakish D; Hooper CL; Filteau MJ; Charbonneau Y; Fraser G; West DL; Thibaudeau C; Raine D
    Psychopharmacol Bull; 1996; 32(1):135-41. PubMed ID: 8927663
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The ventilatory response to cholecystokinin tetrapeptide in healthy volunteers.
    Katzman MA; Duffin J; Shlik J; Bradwejn J
    Neuropsychopharmacology; 2002 Jun; 26(6):824-31. PubMed ID: 12007753
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of repetitive transcranial magnetic stimulation (rTMS) on panic attacks induced by cholecystokinin-tetrapeptide (CCK-4).
    Zwanzger P; Eser D; Völkel N; Baghai TC; Möller HJ; Rupprecht R; Padberg F
    Int J Neuropsychopharmacol; 2007 Apr; 10(2):285-9. PubMed ID: 16817979
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CCK-4: Psychophysiological conditioning elicits features of spontaneous panic attacks.
    Hinkelmann K; Yassouridis A; Mass R; Tenge H; Kellner M; Jahn H; Wiedemann K; Wolf K
    J Psychiatr Res; 2010 Dec; 44(16):1148-53. PubMed ID: 20451215
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Associations between personality traits and CCK-4-induced panic attacks in healthy volunteers.
    Tõru I; Aluoja A; Võhma U; Raag M; Vasar V; Maron E; Shlik J
    Psychiatry Res; 2010 Jul; 178(2):342-7. PubMed ID: 20471107
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lymphocyte cholecystokinin concentrations in panic disorder.
    Brambilla F; Bellodi L; Perna G; Garberi A; Panerai A; Sacerdote P
    Am J Psychiatry; 1993 Jul; 150(7):1111-3. PubMed ID: 8317587
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder.
    Bradwejn J; Koszycki D; Meterissian G
    Can J Psychiatry; 1990 Feb; 35(1):83-5. PubMed ID: 2180549
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cholecystokinin and panic disorder: past and future clinical research strategies.
    Bradwejn J; Koszycki D
    Scand J Clin Lab Invest Suppl; 2001; 234():19-27. PubMed ID: 11713976
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Involvement of dorsolateral periaqueductal gray cholecystokinin-2 receptors in the regulation of a panic-related behavior in rats.
    Bertoglio LJ; Zangrossi H
    Brain Res; 2005 Oct; 1059(1):46-51. PubMed ID: 16168394
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients.
    Bradwejn J; Koszycki D
    Am J Psychiatry; 1994 Feb; 151(2):261-3. PubMed ID: 8296900
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serotonergic compounds in panic disorder, obsessive-compulsive disorder and anxious depression: A concise review.
    Den Boer JA; Westenberg HGM
    Hum Psychopharmacol; 1995 Oct; 10 Suppl 3(S3):S173-S183. PubMed ID: 29569409
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sensitivity to cholecystokinin-tetrapeptide in major depression.
    Koszycki D; Copen J; Bradwejn J
    J Affect Disord; 2004 Jun; 80(2-3):285-90. PubMed ID: 15207943
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors.
    Fux M; Taub M; Zohar J
    Acta Psychiatr Scand; 1993 Oct; 88(4):235-7. PubMed ID: 8256637
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges.
    Kronenberg G; Berger P; Tauber RF; Bandelow B; Henkel V; Heuser I
    Pharmacopsychiatry; 2005 Jan; 38(1):24-9. PubMed ID: 15706463
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder.
    Kellner M; Yassouridis A; Jahn H; Wiedemann K
    Psychopharmacology (Berl); 1997 Sep; 133(1):55-61. PubMed ID: 9335081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.